Zai Lab: Still Attractive Despite Higher Costs And Added Trade War Risks
ZLAB’s Vyvgart revenue has been impressive, rising from roughly $93.6 million in 2024. Read more about ZLAB stock here.
American Association of Individual Investors3d
Which Is a Better Investment, Recursion Pharmaceuticals, Inc. or Zai Lab Limited Stock?
Learn more about whether Recursion Pharmaceuticals, Inc. or Zai Lab Limited is a better investment based on AAII's A+ ...
Fintel on MSN12d
Scotiabank Initiates Coverage of Zai Lab Limited - Depositary Receipt () (ZLAB) with Sector Outperform Recommendation
Fintel reports that on March 7, 2025, Scotiabank initiated coverage of Zai Lab Limited - Depositary Receipt () (NasdaqGM:ZLAB ...
Zai Lab announces acceptance of BLA for TIVDAK in cervical cancer
Zai Lab (ZLAB) “announced that China’s National Medical Products Administration has accepted the Biologics License ...
63,909 Shares in Zai Lab Limited (NASDAQ:ZLAB) Acquired by Zurcher Kantonalbank Zurich Cantonalbank
Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Zai Lab Limited (NASDAQ:ZLAB – Free Report) during the fourth quarter, HoldingsChannel reports. The firm purchased 63,909 ...
Zai Lab price target raised to $51 from $44 at JPMorgan
JPMorgan raised the firm’s price target on Zai Lab (ZLAB) to $51 from $44 and keeps an Overweight rating on the shares. The firm updated models ...
Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has ...
Zai Lab initiated with an Outperform at Scotiabank
Scotiabank initiated coverage of Zai Lab (ZLAB) with an Outperform rating and $55 price target The firm says that although geopolitical risk ...
Analysts Offer Insights on Healthcare Companies: Zai Lab (ZLAB), Perspective Therapeutics (CATX) and Edesa Biotech (EDSA)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Zai Lab (ZLAB – Research Report), Perspective ...
Zai Lab (ZLAB) Initiated with a Buy at Scotiabank
Zai Lab (ZLAB – Research Report) received a Buy rating and a $55.00 price target from Scotiabank analyst Louise Chen today. The company’s ...